PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Back to Search
Print
Bookmark Trial

NCT03423199

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Aichi Cancer Center Hospital
Nagoya, Aichi, 464-8681, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Women 18 years of age or older with histologically or cytologically proven locally advanced or metastatic breast cancer, not amenable to resection or radiation therapy with curative intent

- Documented diagnosis of HR+/HER2- breast cancer

- Any menopausal status

- Previously untreated with any endocrine therapy for their HR+/HER2- advanced breast cancer; or progressed while on or within 3 month from prior endocrine therapy other than tamoxifen for advanced breast cancer. If patients have adjuvant endocrine therapy, they must satisfy as follows: progressed 12 months or more since prior adjuvant endocrine therapy with tamoxifen; or progressed during or after adjuvant endocrine therapy with an aromatase inhibitor.

- Measurable disease or non-measurable disease as defined by RECIST ver.1.1

- Eastern Cooperative Oncology Group (ECOG) PS 0-1

- Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior treatment with any CDK inhibitor, tamoxifen, everolimus, or agent that inhibits
the PI3K-mTOR pathway


- Patients with extensive advanced/metastatic, symptomatic visceral disease, or known
uncontrolled or symptomatic CNS metastases


- Use of strong or moderate CYP3A4 and/or CYP2D6 inhibitors or inducers


- Major surgery or any anti-cancer therapy within 2 weeks of randomization


- Prior stem cell or bone marrow transplantation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Breast NeoplasmsA Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882
  1. Manresa, Barcelona
  2. Terrassa, Barcelona
  3. San Sebastián, Donostia
  4. Las Palmas de Gran Canaria, Gran Canaria
  5. Alcorcón, Madrid
  6. Fuenlabrada, Madrid
  7. Leganés, Madrid
  8. San Sebastián de los Reyes, Madrid
  9. Palma de Mallorca, Mallorca
  10. Pamplona, Navarra
  11. Santa Cruz de Tenerife, Tenerife
  12. Bilbao, Vizcaya
  13. A Coruña,
  14. Albacete,
  15. Alicante,
  16. Barcelona,
  17. Barcelona,
  18. Barcelona,
  19. Barcelona,
  20. Barcelona,
  21. Barcelona,
  22. Cáceres,
  23. Córdoba,
  24. León,
  25. Lugo,
  26. Madrid,
  27. Madrid,
  28. Murcia,
  29. Málaga,
  30. Salamanca,
  31. Sevilla,
  32. Toledo,
  33. Valencia,
  34. Valencia,
  35. Valencia,
  36. Valencia,
  37. Zaragoza,
  38. Zaragoza,
  39. Elche, Alicante
  40. Sagunto, Valencia
  41. Ávila,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsEvaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
NCT00242203
  1. St. Louis, Missouri
Female
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsPAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
NCT03423199
  1. Nagoya, Aichi
  2. Kashiwa, Chiba
  3. Matsuyama, Ehime
  4. Sapporo, Hokkaido
  5. Akashi, Hyogo
  6. Yokohama, Kanagawa
  7. Ōsaka-sayama, Osaka
  8. Minato-Ku, Tokyo
  9. Chiba,
  10. Fukuoka,
  11. Osaka,
  12. Seoul,
  13. Seoul,
  14. Singapore,
  15. Taipei,
  16. Taipei,
  17. Singapore,
  18. Gyeonggi-do,
  19. Soeul,
  20. Tokyo,
  21. Gyeonggi-do,
  22. Taipei,
  23. Gyeonggi-do,
Female
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsPD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT01723774
  1. Birmingham, Alabama
  2. Scottsdale, Arizona
  3. Rochester, Minnesota
  4. Saint Louis, Missouri
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
Official Title  ICMJE Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Brief Summary This study is conducted to evaluate the benefit of adding palbociclib in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer patients, regardless of menopausal status, treated with tamoxifen (with or without goserelin) versus tamoxifen alone (with or without goserelin).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Breast Neoplasms
Intervention  ICMJE
  • Drug: Palbociclib
    Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
    Other Name: PD-0332991
  • Drug: Placebo
    Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
  • Drug: Tamoxifen
    Tamoxifen, 20mg, orally once daily (continuously)
  • Drug: Goserelin
    For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
Study Arms  ICMJE
  • Experimental: Palbociclib + Tamoxifen ± Goserelin
    Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
    Interventions:
    • Drug: Palbociclib
    • Drug: Tamoxifen
    • Drug: Goserelin
  • Active Comparator: Placebo + Tamoxifen ± Goserelin
    Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
    Interventions:
    • Drug: Placebo
    • Drug: Tamoxifen
    • Drug: Goserelin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: February 3, 2018)		180
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 2022
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Women 18 years of age or older with histologically or cytologically proven locally advanced or metastatic breast cancer, not amenable to resection or radiation therapy with curative intent
  • Documented diagnosis of HR+/HER2- breast cancer
  • Any menopausal status
  • Previously untreated with any endocrine therapy for their HR+/HER2- advanced breast cancer; or progressed while on or within 3 month from prior endocrine therapy other than tamoxifen for advanced breast cancer. If patients have adjuvant endocrine therapy, they must satisfy as follows: progressed 12 months or more since prior adjuvant endocrine therapy with tamoxifen; or progressed during or after adjuvant endocrine therapy with an aromatase inhibitor.
  • Measurable disease or non-measurable disease as defined by RECIST ver.1.1
  • Eastern Cooperative Oncology Group (ECOG) PS 0-1
  • Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures

Exclusion Criteria:

  • Prior treatment with any CDK inhibitor, tamoxifen, everolimus, or agent that inhibits the PI3K-mTOR pathway
  • Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases
  • Use of strong or moderate CYP3A4 and/or CYP2D6 inhibitors or inducers
  • Major surgery or any anti-cancer therapy within 2 weeks of randomization
  • Prior stem cell or bone marrow transplantation
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan,   Korea, Republic of,   Singapore,   Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03423199
Other Study ID Numbers  ICMJE NCCH1607
WI217662 ( Other Identifier: Pfizer )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Cancer Center, Japan
Study Sponsor  ICMJE National Cancer Center, Japan
Collaborators  ICMJE
  • Pfizer
  • Korean Cancer Study Group
Investigators  ICMJE
Study Chair:Kan Yonemori, MD, PhDDepartment of Breast and Medical Oncology, National Cancer Center Hospital
PRS Account National Cancer Center, Japan
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP